BAX69 Single-Route Arm
391402
Phase 2 mab terminated
Quick answer
BAX69 Single-Route Arm for Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites is a Phase 2 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites
- Phase
- Phase 2
- Modality
- mab
- Status
- terminated